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Abstract
Background: Many studies using DNA fingerprinting to differentiate Mycobacterium tuberculosis (MTB) strains reveal
single strains in cultures, suggesting that most disease is caused by infection with a single strain. However, recent
studies using molecular epidemiological tools that amplify multiple targets have demonstrated simultaneous
infection with multiple strains of MTB. We aimed to determine the prevalence of MTB multiple strain infections in
Kampala, and the impact of these infections on clinical presentation of tuberculosis (TB) and response to treatment.
Methods: A total of 113 consecutive smear and culture positive patients who previously enrolled in a house-hold
contact study were included in this study. To determine whether infection with multiple MTB strains has a clinical
impact on the initial presentation of patients, retrospective patient data (baseline clinical, radiological and drug
susceptibility profiles) was obtained. To determine presence of infections with multiple MTB strains, MIRU-VNTR
(Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeats) -PCR was performed on genomic
DNA extracted from MTB cultures of smear positive sputum samples at baseline, second and fifth months.
Results: Of 113 patients, eight (7.1%) had infection with multiple MTB strains, coupled with a high rate of HIV
infection (37.5% versus 12.6%, p = 0.049). The remaining patients (105) were infected with single MTB strains. The
proportions of patients with MTB smear positive cultures after two and five months of treatment were similar.
There was no difference between the two groups for other variables.
Conclusion: Infection with multiple MTB strains occurs among patients with first episode of pulmonary
tuberculosis in Kampala, in a setting with high TB incidence. Infection with multiple MTB strains had little impact
on the clinical course for individual patients. This is the first MIRU-VNTR-based study from in an East African
country.
Background
Mycobacterium tuberculosis (MTB) is among the most
successful human pathogens worldwide and is responsi-
ble for extensive morbidity and mortality, with approxi-
mately 2 million deaths each year thought to be due to
primary infection, endogenous reactivation of primary
infection, or exogenous re-infection with a new strain
[1]. Molecular epidemiological studies on transmission
dynamics [2,3] as well as studies on recurrent
tuberculosis (TB) [4,5] have differentiated the MTB
complex strains causing disease. Most studies using
DNA fingerprinting to differentiate mycobacterial strains
have shown single strains in cultures, suggesting that
most disease is caused by infection with a single strain
[6]. However, recent studies using PCR (Polymerase
Chain Reaction) -based molecular epidemiological tools
that amplify multiple targets have demonstrated simulta-
neous infection with multiple strains of MTB. Different
strains have been found in the same sputum sample
[7-11] or different sputum samples from the same
patient [7-9], and in different diseased anatomical sites
of the patient [12,13].
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strains in a population has implications for the interpre-
tation of molecular typing methods, as well as newer
molecular methods for detecting drug resistance. Infec-
tion with multiple strains of MTB may be erroneously
classified as exogenous re-infection or laboratory cross-
contamination. Patients may be infected with both drug
resistant and susceptible strains, of which only one is
detectable through drug resistance testing. This could
affect decisions regarding tuberculosis control and pre-
dictions for patients’ clinical responses to therapy. The
ability of MTB strains to infect a host without generat-
ing immunity to infection by other strains also has
implications for vaccine development. We are yet to
fully understand the prevalence, implication, and factors
associated with infections with multiple MTB strains for
virulence, response to therapy, and clinical presentation.
This study aimed at determining the prevalence of
infection with multiple MTB strains in a high TB inci-
dence setting in Kampala (Kawempe division), Uganda,
using “Mycobacterial Interspersed Repetitive Unit
(MIRU)-Variable-Number Tandem Repeats (VNTR)”
analysis. The incidence of TB in Kawempe division is
high at 920 per 100,000 population per year, similar to
many urban areas in Sub-Saharan Africa [14,15]. Addi-
tionally, because no studies have followed patients with
multiple infections through their treatment course, we
aimed to determine whether infection with multiple
MTB strains results in differences in clinical presenta-
tion or response to treatment.
Methods
Ethical considerations
This study was approved by the Joint Clinical Research
Centre (JCRC) Institutional Review Board (Kampala,
Uganda) and the University Hospitals Cleveland Institu-
tional Review Board (Cleveland, Ohio). Informed written
consent was obtained from patients who participated in
the study.
Study population
Samples were collected from patients with at least one
positive culture for M. tuberculosis who were pre-
v i o u s l ye n r o l l e di nt h eK a w e m p eC o m m u n i t yH o u s e -
hold Contact Study, an ongoing epidemiological study
in Kampala, Uganda, from which several papers have
been published [15-17]. The Kawempe Community
Household Contact study recruits patients who
report not having received treatment for pulmonary
tuberculosis.
Samples were collected consecutively from October
2007 to February 2009, from patients presenting with
pulmonary TB symptoms who reported not having
received treatment for TB in the preceding month.
Demographic and clinical data, including age, sex, HIV
status, and grade of chest radiograph were recorded.
Samples and cultures
For each patient, sputum samples were collected at
baseline and after two and five months of standard,
short-course treatment. Auramine-stained sputum
smears were examined for the presence of acid-fast
bacilli. Samples were decontaminated and processed as
described previously [18] using a standard sodium
hydroxide-sodium citrate method. The processed sam-
ples were inoculated in Bactec-Mycobacterial Growth
Indicator Tubes (MGIT) 960 culture tubes.
Drug susceptibility testing
Drug susceptibility testing was performed on positive
cultures at baseline and after five months of treatment.
DNA extraction
Chromosomal DNA was extracted by centrifuging MTB
cultures and re-suspending the cell pellet in Tris-EDTA
buffer. Cells were then heat-killed at 95°C for 45 minutes,
cooled to room temperature and centrifuged again. The
supernatant containing chromosomal DNA was saved.
Typing by MIRU-VNTR PCR
The MIRU-VNTR PCRs were performed on chromoso-
mal DNA extracted from MTB cultures (described
above). The PCR was designed to amplify a standard set
of 15 MIRU-VNTR loci (580, 2996, 802, 960, 1644,
3192, 424, 577, 2165, 2401, 3690, 4156, 2164b, 1955 and
4052, see Table 1) from genomic DNA extracted from
each sample using primers described by Supply et al
[19] (Table 1). For each reaction, DNA from M. tuber-
culosis H37Rv was used as a positive control, and sterile
water was used as a negative control. PCR products
were electrophoretically separated on 2% agarose gels,
using a 100-bp DNA ladder as size markers. From the
gel images, the corresponding MIRU-VNTR bands were
interpreted as copy numbers based on the reference
table in the Supply 2005 protocol [20]. For any sample
that showed multiple bands at any of the MIRU loci,
the PCR was repeated at least twice in order to confirm
the results. Multiple strains were noted to be present if
a single sample had more than one PCR product at two
or more loci, or if two or more samples from the same
patient differed in copy numbers at two or more loci.
Samples in which copy numbers were different at a sin-
gle locus were considered to represent single strain evo-
lution rather than multiple strains.
Statistical analysis
Comparisons between the groups with multiple versus
single strain infection were made using the student’st
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and multivariate regression analysis. A p value of < 0.05
was considered significant.
Quality control
To avoid laboratory cross-contamination, cultures were
done in small batches ensuring one sample is opened at
a time. For each sample, separate tubes containing the
digestion mixture and phosphate buffer were used to
avoid cross-transfer of specimens. Sterile phosphate buf-
fer was included in the batch being processed, and this
remained negative when cultured. For each patient, mul-
tiple samples were cultured for a given time interval. A
solitary positive sample at a given interval would trigger
investigations for possible cross contamination.
For molecular assays, DNA extraction and PCR were
conducted in a building and laboratory separate from
the culture laboratory. The PCR laboratory has three
separate rooms for Pre-amplification, amplification and
post-amplification. Blank reactions (i.e. where no tem-
plate DNA was added) were used to rule out cross
contamination. A portion of all positive liquid cultures
was used for ZN (Ziehl-Neelsen) staining, blood agar
culture, and IS6110-PCR identification for MTB
complex.
Results
Between October 2007 and February 2009, samples were
collected from a total of 113 patients with pulmonary
tuberculosis. Eight of these patients were infected with
multiple strains of M. tuberculosis, giving a prevalence
of 7.1% (95% CI 2.35-11.81%) for multiple strain infec-
tions in our setting (see Table 2). Three patients who
were infected with single strain were retreatment cases.
At baseline, both patient groups (with multiple and
single MTB strains) had similar proportion of females
and body mass index (BMI). Though the multiple strain
group had a higher median age, higher proportion with
smear-positive tuberculosis, higher average sputum
smear grade, and higher average grade of chest radio-
graph, these did not differ significantly between the two
groups (Table 2). Three of the eight patients with
Table 1 PCR primer sequences and MIRU-VNTR locus designations
1 used in this study
Locus Alias Repeat unit length, bp PCR primer pairs (5’-3’)
580 MIRU4, ETRD 77 GCGCGAGAGCCCGAACTGC
GCGCAGCAGAAACGCCAGC
2996 MIRU26 51 TAGGTCTACCGTCGAAATCTGTGAC
CATAGGCGACCAGGCGAATAG
802 MIRU40 54 GGGTTGCTGGATGACAACGTGT
GGGTGATCTCGGCGAAATCAGATA
960 MIRU10 53 GTTCTTGACCAACTGCAGTCGTCC
GCCACCTTGGTGATCAGCTACCT
1644 MIRU16 53 TCGGTGATCGGGTCCAGTCCAAGTA
CCCGTCGTGCAGCCCTGGTAC
3192 MIRU31, ETRE 53 ACTGATTGGCTTCATACGGCTTTA
GTGCCGACGTGGTCTTGAT
424 Mtub04 51 CTTGGCCGGCATCAAGCGCATTATT
GGCAGCAGAGCCCGGGATTCTTC
577 ETR C 58 CGAGAGTGGCAGTGGCGGTTATCT
AATGACTTGAACGCGCAAATTGTGA
2165 ETR A 75 AAATCGGTCCCATCACCTTCTTAT
CGAAGCCTGGGGTGCCCGCGATTT
2401 Mtub30 58 CTTGAAGCCCCGGTCTCATCTGT
ACTTGAACCCCCACGCCCATTAGTA
3690 Mtub39 58 CGGTGGAGGCGATGAACGTCTTC
TAGAGCGGCACGGGGGAAAGCTTAG
4156 QUB-4156 59 TGACCACGGATTGCTCTAGT
GCCGGCGTCCATGTT
2163b QUB-11b 69 CGTAAGGGGGATGCGGGAAATAGG
CGAAGTGAATGGTGGCAT
1955 Mtub21 57 AGATCCCAGTTGTCGTCGTC
CAACATCGCCTGGTTCTGTA
4052 QUB-26 111 AACGCTCAGCTGTCGGAT
CGGCCGTGCCGGCCAGGTCCTTCCCGAT
1: Extracted from Supply et al, [19]. Primers were synthesized by Eurofins MWG Operon, Ebersberg (Germany).
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while 13 (12.62%) of those with single strain infections
were HIV positive (p = 0.0494).
The underlying co-morbidities, as well as radiological
findings and drug resistance profiles that were found in
patients with single and multiple strain infections are
summarized in Table 2. The number of patients with
multiple strain infections was too small to make strong
conclusions about these findings. Only one patient, who
was infected with a single MTB strain, had multi-drug
resistant tuberculosis.
Both groups had a similar proportion of patients with
positive cultures after two months of treatment (multi-
ple strains 25.00%, single strain 25.74%, p = 0.95). Four
patients had positive cultures after five months, all of
them infected with single strains (p = 0.5428).
Of the eight patients with multiple strain infections,
seven had multiple strains in their baseline samples and
only three had positive month two (M2) cultures. How-
ever, two of the M2 cultures were unrecoverable and
the available M2 culture was confirmed with multiple
strain infections. None of the eight patients had positive
month five (M5) cultures (Table 3). Of the other seven
patients, three had multiple strains in a single sputum
sample, and four had different strains in different spu-
tum samples.
Discussion
This study demonstrates that infection with multiple
strains of MTB occurs among patients with first epi-
sodes of pulmonary TB in a high-incidence community
setting of Kampala. The prevalence of multiple strain
infection in our cohort was 7.1%, the first MIRU-
VNTR-based estimate from an East African country. In
our study, the MIRU-VNTR loci were amplified using a
single target ordinary PCR which, although proven sen-
sitive, has a limit on detection and could have missed
some infections with multiple MTB strains. Studies
from similar high-incidence settings in South Africa
showed multiple infection rates of 19%, in which PCR-
based methods differentiated Beijing versus non-Beijing
lineages, and 4.8% using spoligotyping [11], as well as
2.3% using IS6110 restriction fragment length poly-
morphism (RFLP) [9]. It is possible that the varying esti-
mates are a reflection of differences in sensitivities of
each method in detecting multiple MTB strains in spu-
tum cultures, with PCR-based methods being more sen-
sitive than RFLP. Presumably, a lower estimate of
infections with multiple MTB strains would have been
found had we used RFLP analysis in this cohort.
Baseline clinical presentations appear to be similar for
patients with multiple and single strain infections. There
was a higher rate of HIV infection in the multiple strain
group, though this difference was not statistically signifi-
cant using multivariate regression analysis. This study
was limited by a relatively small sample size; further stu-
dies using a larger cohort would be useful in confirming
or refuting these results. The average CD4 counts for
patients with multiple versus single strain infection were
similar, and patients with multiple strains had a wide
range of baseline CD4 counts. If indeed HIV infection
results in increased susceptibility to multiple strain
Table 2 Prevalence of multiple infections with
M. tuberculosis and comparison between patients with
multiple versus single strain infections
Patients with pulmonary tuberculosis, N = 113
Multiple strain infection, % (95% CI), 7.08% (2.35-11.81)
Multiple
strains,
n=8
Single
strain,
n = 105
p
value
Baseline data
Age (median, years) 34.5 25 0.0745
Sex (% female) 50 51.89 0.8965
Body Mass Index (mean) 20.73 19.17 0.1764
HIV Positive (%) 37.5 12.62 0.0494
Sputum Smear Positive (%) 100 84.62 0.2169
Sputum Smear Grade (mean) 3.12 2.82 0.5511
Multidrug Resistance, n 0 1 0.8137
Culture positive after 2 months
(%)
25.00 25.74 0.95
Culture positive after 5 months
(%)
0 4.54 0.5379
Chest X-ray
1
Grade 0 (%) 25 8 0.1482
Grade 1 (%) 0 16
Grade 2 (%) 0 25
Grade 3 (%) 63 41 0.2813
Co-morbidities
Respiratory tract infections (%) 88 53 0.0607
Malaria (%) 25 29 0.8289
Candidiasis (%) 25 6 0.0404
Anemia (%) 13 2 0.0723
PUD (%) 13 1 0.0170
Drug resistance profiles
INH (%) 25 4 0.0573
RMP (%) 0 1
EMB (%) 0 0
PZA (%) 0 0
STM (%) 0 2
CI, Confidence Interval;
1baseline chest x-ray data; PUD, Peptic ulcer disease;
INH, Isoniazid; RMP, Rifampicin; EMB, Ethambutol; PZA, Pyrazinamide; STM,
Streptomycin
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just as HIV-infected patients are more susceptible to TB
disease at any CD4 count [21].
There was no difference in response to anti-tuberculo-
sis treatment between the multiple and single infection
groups; each group had similar rates of culture positivity
after two and five months. There was a low rate of drug
resistance in our cohort, similar to the overall rate in
Uganda for multi-drug resistant TB (0.5% of new cases)
[15]. Indeed, only one patient who was infected with a
single MTB strain had MDR-TB.
The presence of infections with multiple MTB strains
in this setting had little impact on the clinical course for
individual patients. Multiple strain infections did not
alter initial presentation or response to treatment. Addi-
tionally, drug resistance testing in our setting was not
affected by the presence of multiple strains, but this
seems to be mostly due to a low level of resistant strains
in this community. In a setting with higher rates of drug
resistance as well as a high level of TB transmission, it
would seem likely that drug resistance testing can be
complicated by multiple strain infections.
It is difficult to determine the timing of infection by
individual strains resulting in multiple strain infections.
Patients may be infected simultaneously by two or more
strains, or an initial infection may be inadequate in pro-
viding immunity to subsequent re-infection with a new
strain. It is also difficult to measure proportions of
growth of different strains during the course of disease
and which strains are primarily responsible for driving
disease progression. Consequently, the results of mole-
cular epidemiologic studies of TB transmission and
recurrent disease should be interpreted in light of the
possibility of multiple strain infection and varying trans-
mission. When possible, such studies should employ
methods sensitive enough to detect multiple infections.
Table 3 MIRU-VNTR genotypes of M. tuberculosis isolates from patients with multiple strain TB infections
MIRU-VNTR Locus amplified
PTID Time point Sample 580 960 1644 2996 3192 802 424 577 1955 2163 2165 2401 3690 4052 4156
A BL 35357 2,5 2 4,5 3,4,6 1,3,5 3,4,6 4 2,6 1,3 4 1,2 3 2,6 5
BL 35358 2,5 2 4,5 4 1,3 4 4 2 1 1 2
B BL 33007 2 5 1,3,4 4,6 4 4,6,7 5 2 1,2,3 3 2,3,5 4
C BL 34347 2 5 1 3 2 4 5 4 2 2 2 3
BL 34348 2 5 1 3 2,3 3,4,5 5,4,3 2,3,4 2 2,3,4 2,3,4 3
D BL 33914 2 4 4 4 2 3 4 3 3 2 4 4423
BL 33913 2 4 4 3 1 2 4 3 2 4 2 2 3
E BL 35584 2 2 3 3 3 4 2 4 3 2 3 2238
BL 35583 3 4 5 3 2 3 2 4 2 2 4 2433
F BL 37768 2 1 1 2 1 2 4 2 2 2 2 2 3
BL 37767 2 5 1 3 1 3 4 5 2 1 2 2 2 3
G BL 38228 2 7 3 6,8 5 4 2 2,3,4 4 3 6 4 9
H BL 33027 MOTT
BL 33026 MOTT
M2 33608 2’ 5 3646 5 2 233 4
M2 33609 2 5 3 4,6 5 2,3 2 3 2, 3 4
M2 33610 2’ 51 6 452 2 3 3 4
The numerical figures (1 to 9) represent the number of alleles per amplified MIRU-VNTR loci, as described by Supply et al [19,20]. Where there is more than one
numerical figure per locus implies existence of more than one MTB strain in the sample, indicating multiple strain infection with M. tuberculosis (Patient samples
A, B, C, and G). Serial samples from patients D, E, F, and H had different strains at different sampling points, which also indicate multiple strains infection. For
patients A-G, blanks in copy numbers are presumed to be due to technical laboratory error. For patient H, blanks are likely due to MOTT co-infection.
2’ is a standard copy number noted in the MIRU manual; PTID, Patient Identification; BL, Baseline sample collection; M2, sample collection in the second month;
MOTT, Mycobcateria Other Than Tuberculosis
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subsequent infection adds to our understanding of host
immunity and may influence development of an effec-
tive vaccine. The presence of multiple strains in 7.1% of
TB patients in this setting also implies that there is a
high rate of transmission and re-infection, emphasizing
the importance of TB control in efforts to eradicate this
disease.
One of the limitations in our study is that the MIRU-
VNTR-PCR was done on genomic DNA extracts from
cultured samples of MTB positive smears, and we could
have missed MIRU-VNTR-positives from negative
smear samples. However, doing direct PCR on sputum
samples is associated with problems of sampling and
inhibitors [22].
Conclusion
Multiple strain infections occur among patients with
first episodes of pulmonary tuberculosis in Kampala, in
a setting with a high tuberculosis incidence. The pre-
sence of multiple strain infections had little impact on
the clinical course for individual patients.
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